Difficult Cases in Breast Cancer - 2020 Annual Meeting
It is imperative that radiation oncologists remain current in state of the art clinical trials, and moreover that they understand how to utilize this data to provide appropriate patient care. This difficult cases panel will allow participants a window into how the expert panel uses modern data and clinical experience to guide clinical decision-making.
This activity is available from March 1 2021, through 11:59 p.m. Eastern time on February 29, 2024.
This activity was originally recorded at ASTRO’s virtual 2020 Annual Meeting, October 23-28th.
The activity is designed to meet the interests of radiation oncologists, nurses, and radiation oncology residents.
Upon completion of this activity, learners should be able to:
- Identify the appropriate indications for hypofractionation, and be ready to integrate this into their practice.
- Describe the controversies surrounding management of the axilla, and be able to utilize this knowledge to appropriately council patients and make treatment decisions.
- Jennifer Bellon, MD, FASTRO is employed at Brigham and Women's Hospital, receives compensation from Leidos Pharaceutical and Varian Medical Systems. Dr. Bellon has a research grant from Prosigna.
- Julia Wong, MD is employed at Brigham and Women's Hospital and has no financial relationships with a commercial interest.
- Catherine Park, MD, FASTRO is employed at UCSF, has investment interest from Oncosynergy and Merck. Dr. Park has family who has investment interest from Telotherapeutics, Inc.
- Barbara Smith, MD is employed at Massachusetts General Hospital and has no financial relationships with a commercial interest.
- Benjamin Smith, MD, FASTRO is employed at UT MD Anderson Cancer Center and has family employed at UT MD Anderson Cancer Center. Dr. Smith has Patent/License Fees/Copyright: Royalty from Oncora Medical.
- Sara Tolaney is employed at Dana Farber Cancer Institute and has research grants from AstraZeneca, Bristol-Meyers Squbb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech, Immunomedics, Merck, Nanostring, Nektar, Novartis, Odonate, Pfzier, Sanofi, Seattle Genetics. Dr. Tolaney has investment interest and receives compensation from Abbvie, AstraZeneca, Athenex, Bristol-Meyers Squibb, Celldex, CytomX, Daiichi-Sankyo, Eisai, Eli Lily, Genentech, Immunomedics, Kyowa Kirin Pharmaceuticals, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Paxman, Odonate, OncoPep, Pfizer, Puma, Samsung Bioepsis Inc., Sanofi, Seattle Genetics.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.